A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2019
Price : $35 *
At a glance
- Drugs SR T100 (Primary)
- Indications Warts
- Focus Therapeutic Use
- Sponsors G&E Herbal Biotechnology
- 12 Jul 2019 Planned End Date changed from 1 Dec 2019 to 1 Mar 2021.
- 12 Jul 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
- 12 Jul 2019 Status changed from not yet recruiting to suspended.